D:	ate:Jan. 04, 2022			
	our Name: Lu Gao			
		modulates CDK4/	6 inhibitors resistance in metastatic breast cancer by R	b1
	utations: a case report and literature		The state of the s	~_
Manuscript number (if known):				
	(/· <u></u>			
re pa to	elated to the content of your manuscri arties whose interests may be affected	ipt. "Related" mea d by the content o ly indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitmen If you are in doubt about whether to list a so.	
	ne following questions apply to the au anuscript only.	thor's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to	• •	ou should declare	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertens he manuscript.	
	item #1 below, report all support for se time frame for disclosure is the pas	•	d in this manuscript without time limit. For all other it	ems,
	Name al	l entities with	Specifications/Comments	
	whom y	ou have this	(e.g., if payments were made to you or to your	
	relations	ship or indicate	institution)	
	-	dd rows as		
	needed)			
	Time fra	me: Since the initial	planning of the work	

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^NOTIE	+
	Perionia		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	X None	
10	Leadership or fiduciary role in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:
			1
	None.		
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:

Date:Jan. 04, 2022 Your Name: Xia-bo Shen Manuscript Title: Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^NOTIE	+
	Perionia		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	X None	
10	Leadership or fiduciary role in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:
			1
	None.		
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:

Date:____Jan. 04, 2022_

Consulting fees

_X__None

Yo	ur Name: Li-bin He			
		therapy modulates CDK4/	6 inhibitors resistance in metastatic breast cancer by Rb	1
	utations: a case report and li		•	
	anuscript number (if known)			
	,			
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the graph of the profit of the manuscript. If you are in doubt about whether to list a poso.	
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to		ension, you should declare	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.	
	item #1 below, report all su e time frame for disclosure i	• •	d in this manuscript without time limit. For all other ite	ms,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the initia	planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: past	36 months	
2	Grants or contracts from	Time frame: pastXNone	36 months	
2	Grants or contracts from any entity (if not indicated	•	36 months	
2		•	36 months	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^NOTIE	+
	Perionia		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	X None	
10	Leadership or fiduciary role in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:
			1
	None.		
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:

Date:Jan. 04, 2022	
Your Name:Jia-yi Wu	
Manuscript Title: Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by RI mutations: a case report and literature review	b1
Manuscript number (if known):	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third	

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

_			
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
U	testimony	XNone	
	созинону		+
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X None	
O	pending	^_NOTIE	+
	Perionia		+
	Deutici II	V N	
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
10	Advisory Board	X None	
10	Leadership or fiduciary role in other board, society,	^_Notie	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests		
Ple	ase summarize the above c	onflict of interest in the fo	llowing box:
			1
	None.		
Ple	ase place an "X" next to the	e following statement to in	ndicate your agreement:

Date:Jan. 04, 2022
Your Name:Yi-yuan Liu
Manuscript Title: Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb2
mutations: a case report and literature review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
			-
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_				
5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
U	testimony	XNone		
	созинону		+	
7	Support for attending	X None		
	meetings and/or travel			
8	Patents planned, issued or	X None		
O	pending	^NOTIE	+	
	Perionia		+	
	Deutici II	V N		
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
10	in other board, society,	^_Notie		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	2000. St Stock options			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None		
	services			
13	Other financial or non-	X None		
13	financial interests			
	idilolal litterests			
			1	
Ple	Please summarize the above conflict of interest in the following box:			
_				
	None.			
Ple	ease place an "X" next to the	e following statement to in	ndicate your agreement:	

Date:Jan. 04, 2022
our Name:Xiao-jia Wang
Manuscript Title: Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1
nutations: a case report and literature review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_				
5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
U	testimony	XNone		
	созинону		+	
7	Support for attending	X None		
	meetings and/or travel			
8	Patents planned, issued or	X None		
O	pending	^_NOTIE	+	
	Perionia		+	
	Deutici II	V N		
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board			
10	Leadership or fiduciary role	X None		
10	in other board, society,	^_Notie		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	2000. St Stock options			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None		
	services			
13	Other financial or non-	X None		
13	financial interests			
	idilolal litterests			
			1	
Ple	Please summarize the above conflict of interest in the following box:			
_				
	None.			
Ple	ease place an "X" next to the	e following statement to in	ndicate your agreement:	

Date:Jan. 04, 2022
Your Name:Xi-ying Shao
Manuscript Title: Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb2
mutations: a case report and literature review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
			-
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_				
5	Payment or honoraria for lectures, presentations,	XNone		
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	X None		
U	testimony	XNone		
	созинону		+	
7	Support for attending	X None		
	meetings and/or travel			
8	Patents planned, issued or	X None		
O	pending	^NOTIE	+	
	Perionia		+	
	Deutici II	V N		
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
10	Advisory Board Leadership or fiduciary role	X None		
10	in other board, society,	^_Notie		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X None		
	2000. St Stock options			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None		
	services			
13	Other financial or non-	X None		
13	financial interests			
	idilolar irrect ests			
			1	
Ple	Please summarize the above conflict of interest in the following box:			
_				
	None.			
Ple	ease place an "X" next to the	e following statement to in	ndicate your agreement:	